Exemestane in Breast Cancer Treatment: Literature Review
DOI:
https://doi.org/10.54097/t83apt51Keywords:
Exemestane, breast cancer (BC), hormone receptor-positive (HR+), oestrogen receptor-positive (ER+), premenopausal, postmenopausal, adjunctive therapy; early-stage BC, advanced BC.Abstract
Breast cancer (BC) is a pervasive global health concern, impacting millions each year. This literature review explores the role of exemestane in BC treatment. Exemestane inhibits the development of hormone receptor-positive (HR+) BC by drastically lowering oestrogen levels. Its efficacy is evident in early and advanced BC stages, with potential cost-effectiveness. While predominantly used in postmenopausal women, it shows promise in premenopausal patients when combined with ovarian suppression. Caution is needed in elderly populations when combined with other drugs, as adverse effects are more pronounced. Exemestane emerges as a crucial therapeutic tool, necessitating personalized treatment decisions for optimal patient outcomes.
Downloads
References
Adon, T., Shanmugarajan, D., Ather, H., Ansari, S. M., Hani, U., Madhunapantula, S. V., & Honnavalli, Y. K. (2023). Virtual screening for identification of dual inhibitors against CDK4/6 and aromatase enzyme. Molecules, 28 (6), 2490.
Wang, Y., Jing, F., & Wang, H. (2022). Role of Exemestane in the treatment of estrogen-receptor-positive breast cancer: A narrative review of recent evidence. Advances in Therapy, 39 (2), 862 – 891.
Barzaman, K., Karami, J., Zarei, Z., Hosseinzadeh, A., Kazemi, M. H., Moradi-Kalbolandi, S., Safari, E., & Farahmand, L. (2020). Breast cancer: Biology, biomarkers, and treatments. International Immunopharmacology, 84, 106535.
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., Cristofanilli, M., Hortobagyi, G. N., & Pusztai, L. (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology, 26 (8), 1275 – 1281.
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation, 121 (7), 2750 – 2767.
Beklen, H., Arslan, S., Gulfidan, G., Turanli, B., Ozbek, P., Karademir Yilmaz, B., & Arga, K. Y. (2021). Differential interactome based drug repositioning unraveled abacavir, exemestane, nortriptyline hydrochloride, and tolcapone as potential therapeutics for colorectal cancers. Frontiers in Bioinformatics, 1.
Lombardi, P. (2002). Exemestane, a new steroidal aromatase inhibitor of clinical relevance. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1587 (2–3), 326 – 337.
Lombardi, P. (1995). The irreversible inhibition of aromatase (oestrogen synthetase) by steroidal compounds. Current Pharmaceutical Design, 1 (1), 23 – 50.
Miller, W. R. (1996). Aromatase inhibitors. Endocrine Related Cancer, 3 (1), 65 – 79.
Pritchard, K. I., Burris, H. A., Ito, Y., Rugo, H. S., Dakhil, S., Hortobagyi, G. N., Campone, M., Csöszi, T., Baselga, J., Puttawibul, P., Piccart, M., Heng, D., Noguchi, S., Srimuninnimit, V., Bourgeois, H., Gonzalez Martin, A., Osborne, K., Panneerselvam, A., Taran, T., Sahmoud, T., Gnant, M. (2013). Safety and efficacy of everolimus with Exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor–positive breast cancer in bolero-2. Clinical Breast Cancer, 13 (6), 421 - 432.e8.
Yip, C.-H., & Rhodes, A. (2014). Estrogen and progesterone receptors in breast cancer. Future Oncology, 10 (14), 2293 – 2301.
Untch, M., & Jackisch, C. (2008). Exemestane in early breast cancer: A Review. Therapeutics and Clinical Risk Management, 4 (6), 1295 – 1304. https: //doi.org/10.2147/tcrm.s4007.
Fabian, C. J. (2007). The what, why and how of aromatase inhibitors: Hormonal agents for treatment and prevention of breast cancer. International Journal of Clinical Practice, 61 (12), 2051 – 2063.
Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., Gomez, H. L., Tondini, C., Burstein, H. J., Perez, E. A., Ciruelos, E., Stearns, V., Bonnefoi, H. R., Martino, S., Geyer, C. E., Pinotti, G., Puglisi, F., Crivellari, D., Ruhstaller, T., Winer, E. P., Rabaglio-Poretti, M., Maibach, R., Ruepp, B., Giobbie-Hurder, A., Price, K. N., Bernhard, J., Luo, W., Ribi, K., Viale, G., Coates, A.S., Gelber, R. D., Goldhirsch, A., Francis, P. A. (2014). Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. New England Journal of Medicine, 371 (2), 107 – 118.
Deeks, E. D., & Scott, L. J. (2009). Exemestane. Drugs, 69 (7), 889 – 918.
Wildiers, H., & de Glas, N. A. (2020). Anticancer drugs are not well tolerated in all older patients with cancer. The Lancet Healthy Longevity, 1 (1), e43 – e47.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
